Predicting Fatal Drug Poisoning Among People Living with HIV‑HCV Co‑Infection
Mélanie Bédard, Erica Em Moodie, Joseph Cox, John Gill, Sharon Walmsley, Valérie Martel‑Laferrière, Curtis Cooper, Marina B Klein, Canadian Liver Journal, 2025
CRISM is a national network of researchers, service providers, policy makers, and people with lived experience of substance use. Its main goal is to translate evidence-based interventions into clinical practice, community prevention, harm reduction, and health system improvements. The aim is to support the creation of more effective, personalized, and adoptable programs and services.
Substance use disorders are pressing and complex health issues. Effective interventions require evidence-based approaches, an understanding of biological, psychosocial, and social factors, and recognition of the influence of cultural, societal, and policy contexts. While many intervention modalities have proven results, they are not yet widely implemented.
To address these translation and implementation gaps, the Canadian Institutes of Health Research (CIHR), through its Institute for Neurosciences, Mental Health, and Addiction (INMHA), developed the Canadian Research Initiative in Substance Matters (CRISM) (previously known as the Canadian Research Initiative in Substance Misuse). CRISM was designed to facilitate communication and collaboration across the pillars of addiction service providers, researchers, policy-makers, patients, and people who use substances. CRISM is a network that consists of five regional teams (referred to as Nodes), located in BC, the Prairies, Ontario, Québec, and the Atlantic region.
Provide evidence to support the enhancement of prevention and treatment services regarding substance use to decision makers and service providers
Identify and/or develop the most appropriate clinical and community-based interventions for substance use disorders
Support improvement in the quality of life for Canadians living with substance use
Mélanie Bédard, Erica Em Moodie, Joseph Cox, John Gill, Sharon Walmsley, Valérie Martel‑Laferrière, Curtis Cooper, Marina B Klein, Canadian Liver Journal, 2025
Karamouzian M, Cui Z, Hayashi K, DeBeck K, Reddon H, Buxton J, Kerr T, Int J Drug Policy
Stine Bordier Høj, Rémi Coignard‑Friedman, Aissata Sako, Catherine de Montigny, Marie‑Ève Beauchemin‑Nadeau, Robert Léandre, Nanor Minoyan, Geneviève Boyer‑Legault, Sofiane Chougar, Sara‑Kim Lamont, Julie Bruneau, Harm Reduction Journal , 2025
Lim J, Bruneau J, Platt RW, Panagiotoglou D., Drug Saf. 2025
Parker DG, Radin S, Sorlagas N, Wendt DC., Health Res. 2025
Bastien G, Abboud A, McAnulty C, Mahroug A, Le Foll B, Socias ME, Juteau LC, Dubreucq S, Jutras-Aswad D., Can J Psychiatry. 2025
Ali, F., Law, J., Russell, C., Imtiaz, S., Bayoumi, A., Werb, D., Rhem, J., Front. Public Health
Bach P, Le Foll B, Davidson S, de Kiewit A, Bakouni H, Poulin G, Ghosh M, Jutras-Aswad D., Contemp Clin Trials. 2025
Nanor Minoyan, Stine Bordier Høj, Didier Jutras‑Aswad, Sarah Larney, Valérie Martel‑Laferrière, Marie‑Pierre Sylvestre, Julie Bruneau, International Journal of Mental Health and Addiction, 2025
Bastien G, McAnulty C, Sharafi H, Mahroug A, Elkrief L, Ziegler D, Dubreucq S, Juteau LC, Jutras-Aswad D., J Addict Med. 2025
Matthew Carwana, Eva Moore, Helia Shariati, Hasina Samji, Nicholas Chadi, Paediatrics & Child Health, 2025